• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

White Superficial Onychomycosis

Article

These small areas of white dyschromia are typical of white superficial onychomycosis, often due to dermatophyte invasion following minor trauma. This form of onychomycosis usually responds well to topical therapy.

A 56-year-old woman sought medical attention because of discoloration of both great toenails.

Key point: The patient’s great toenails both exhibited small areas of white dyschromia, but lacked subungual hyperkeratosis or alterations in overall nail shape. This is typical for white superficial onychomycosis, often due to dermatophyte invasion following minor trauma. The patient played tennis daily.

Treatment: The patient responded well to topical application of ciclopirox 0.7% nail lacquer.

Note: In contrast to the more typical form of onychomycosis, which requires systemic antifungal therapy, white superficial onychomycosis usually responds to topical treatment.

Related Content
Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose

Sydney Jennings
November 7th 2024
Article

Your daily dose of the clinical news you may have missed.

When is It Time to Refer: A Dermatologist Considers Atopic Dermatitis Treated in Primary Care / Image credit Central Connecticut Dermatology

When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care

Grace Halsey
November 7th 2024
Article

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD / image credit Central Connecticut Dermatology

Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD

Grace Halsey
November 6th 2024
Article

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children / image credit ©Organon

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children

Grace Halsey
November 5th 2024
Article

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Atopic Dermatitis: Final ADORING 3 Open-Lael Extension Trial Findings with Tapinarof 1% Announced / image credit atopic dermatitis concept ©New Africa/stock.adobe.com

Atopic Dermatitis: Final ADORING 3 Open-Label Extension Trial Findings with Tapinarof Cream, 1% Announced

Grace Halsey
October 31st 2024
Article

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Ryan Flinn
October 25th 2024
Article

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

© 2024 MJH Life Sciences

All rights reserved.